A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Phase: PHASE2, PHASE3 | Sponsor: COMPASS Pathways | Compound: Psychedelic

Status

planned

Institution

COMPASS Pathways

Start date

2026-09-01

End date

2029-09-01

Registry ID

NCT07570654

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.